lymphoma

Omidubicel, a new cellular therapy, expands the availability of allogeneic (donor) stem cell transplants to more patients.

Learn about new developments in next generation molecular sequencing tests at the DUHS Clinical Labs' Clinical Molecular Diagnostics Laboratory.

The color blue and butterflies always make Jamie Cooper Moales think of her late sister, Sara Elizabeth Cooper.

A gift from the family of pancreatic cancer survivor Nancy Wright helps spread the sound of hope in the Duke cancer community. 

Clinical providers, researchers, staff & health leaders came together to celebrate the 50th anniversary of the Duke Comprehensive Cancer Center (now DCI).

The Eighth Annual DCI Scientific Retreat was one for the books.

Three years ago the retired NCCU Dean of Student Learning, 73, walked 60 miles to raise money for breast cancer. Now she's facing down an aggressive lymphoma.

Join Team DCI and "Light the Night" Oct. 21 to support blood cancer awareness and research. The virtual program includes a ceremony, lantern raising, social celebration & fireworks.

This OHE event, taped Aug. 19, focused on leukemia, lymphoma, and multiple myeloma: risk factors, symptoms, diagnosis,  latest treatments.

The new Duke Blood Cancer Center opens up the opportunity to transition some cancer treatments from the inpatient to the outpatient setting and the infusion room is open every day.

Madelyn Wilson finds that getting involved with Duke's Teen and Young Adult Oncology Program a way to finding purpose after ending active cancer treatment.

In observance of Blood Cancer Awareness Month, Denise Spector, PhD, shares her husband's final months spent fighting cancer and thanks his heroes on 9100.

At Duke, Bob Porter of Greenville, South Carolina, found the most caring doctor he ever met.

Teen and young adult cancer patients will receive expanded services at Duke, thanks to a $400,000 award from First Citizens Bank and Teen Cancer America.

In January, DCI joined a select group of medical centers authorized to offer CAR T-cell therapy for patients with with certain types of relapsed or refractory non-Hodgkin’s lymphoma.

Why do perfectly good cancer treatments suddenly stop working? Researcher and lymphoma survivor Kris Wood is finding answers.